![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » LivaNova Aortic Valves Approved for Expanded Use Labeling
LivaNova Aortic Valves Approved for Expanded Use Labeling
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
LivaNova earned a CE Mark and approval for expanded use of its Bicarbon aortic valves with lower dose blood thinners in low-risk patients.
The expansion means that a lower international normalized ratio — the standard for measuring blood coagulability — can be targeted following implantation of the valve in low-risk patients going through mechanical aortic valve replacement.
After implanting the aortic heart valves in patients with low risk of thromboembolic events, physicians can work with a lower-range level of anticoagulant therapy, potentially reducing the risk of bleeding without the increased risk of blood clots.
Upcoming Events
-
21Oct